Portfolio Company Exonate Ltd. lead candidate EXN407 demonstrates safety and biological activity in phase Ib/IIa clinical trial

Portfolio company EXONATE LIMITED have recently announced the full data from their Phase Ib/IIa trial for diabetic retinopathy and diabetic macular oedema.

The results, set to be presented at the Association for Research in Vision and Ophthalmology (ARVO) in May 2024, not only confirm the safety of their lead candidate, EXN407, but also highlight its promising biological activity. This positive data further supports the progression of EXN407 to the CLEAR-DM Phase IIb study, bringing us one step closer to a non-invasive topical treatment option for retinal vascular diseases.

Huge congrats to the team!

To read more on this announcement, visit https://rb.gy/kz5gx8